Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Standards
|
![]() |
Ceritinib for untreated ALK-positive non-small-cell lung cancerNICE Guidance, 2018Copyrights: © NICE 2018 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
2 |
Material Type: Standards
|
![]() |
Tocilizumab for treating giant cell arteritisNICE Guidance, 2018Copyrights: © NICE 2018 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
3 |
Material Type: Standards
|
![]() |
Midostaurin for untreated acute myeloid leukaemiaNICE Guidance, 2018Copyrights: © NICE 2018 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
4 |
Material Type: Standards
|
![]() |
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisNICE Guidance, 2019Copyrights: © NICE 2019 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
5 |
Material Type: Standards
|
![]() |
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery diseaseNICE Guidance, 2019Copyrights: © NICE 2019 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
6 |
Material Type: Standards
|
![]() |
Lenalidomide with rituximab for previously treated follicular lymphomaNICE Guidance, 2020Copyrights: © NICE 2020 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
7 |
Material Type: Standards
|
![]() |
Avelumab with axitinib for untreated advanced renal cell carcinomaNICE Guidance, 2020Copyrights: © NICE 2020 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
8 |
Material Type: Standards
|
![]() |
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyNICE Guidance, 2020Copyrights: © NICE 2020 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
9 |
Material Type: Standards
|
![]() |
Metreleptin for treating lipodystrophyNICE Guidance, 2021Copyrights: © NICE 2021 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
10 |
Material Type: Standards
|
![]() |
Berotralstat for preventing recurrent attacks of hereditary angioedemaNICE Guidance, 2021Copyrights: © NICE 2021 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
11 |
Material Type: Standards
|
![]() |
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoeaNICE Guidance, 2021Copyrights: © NICE 2021 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
12 |
Material Type: Standards
|
![]() |
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerNICE Guidance, 2021Copyrights: © NICE 2021 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
13 |
Material Type: Standards
|
![]() |
Nintedanib for treating progressive fibrosing interstitial lung diseasesNICE Guidance, 2021Copyrights: © NICE 2021 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
14 |
Material Type: Standards
|
![]() |
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersNICE Guidance, 2021Copyrights: © NICE 2021 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
15 |
Material Type: Standards
|
![]() |
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableNICE Guidance, 2022Copyrights: © NICE 2022 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
16 |
Material Type: Standards
|
![]() |
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableNICE Guidance, 2022Copyrights: © NICE 2022 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
17 |
Material Type: Standards
|
![]() |
Ponesimod for treating relapsing–remitting multiple sclerosisNICE Guidance, 2022Copyrights: © NICE 2022 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
18 |
Material Type: Standards
|
![]() |
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaNICE Guidance, 2022Copyrights: © NICE 2022 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
19 |
Material Type: Standards
|
![]() |
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableNICE Guidance, 2022Copyrights: © NICE 2022 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
20 |
Material Type: Standards
|
![]() |
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyNICE Guidance, 2022Copyrights: © NICE 2022 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |